ATOS Atossa Genetics Inc.

2.07
-0.05  -2%
Previous Close 2.12
Open 2.12
Price To Book 0.97
Market Cap 18,888,195
Shares 9,124,732
Volume 154,301
Short Ratio
Av. Daily Volume 537,436

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial to be completed 4Q 2019.
Endoxifen
Healthy volunteers
Phase 2 data met primary endpoint - June 27, 2019. High dropout rate noted.
Endoxifen
Mammographic breast density (MBD)
Phase 2 trial ongoing - noted December 28, 2017.
Fulvestrant
Cuctal carcinoma in situ(DCIS) - invasive breast cancer
Phase 1 preliminary data September 13, 2018 noted drug met safety and tolerability objectives. Final data January 9, 2019 confirmed objectives met.
Endoxifen
Male breast cancer and Gynecomastia
Phase 2 commencement of enrollment announced July 13, 2018.
Endoxifen
Breast cancer - window of opportunity setting

Latest News

  1. Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated
  2. A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019
  3. Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
  4. Some Atossa Genetics (NASDAQ:ATOS) Shareholders Have Copped A 99% Share Price Wipe Out
  5. Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019
  6. Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update
  7. "The Digital Economy & World Markets"
  8. Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit
  9. Reducing This Amino Acid May Aid In Fight Against Breast Cancer
  10. Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019
  11. Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update
  12. "Bull Market Hopping?"
  13. Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
  14. Atossa Genetics Announces Receipt of $10 Million
  15. What Type Of Shareholder Owns Atossa Genetics Inc.’s (NASDAQ:ATOS)?
  16. Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing
  17. Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
  18. "On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter
  19. Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues
  20. Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force